SSG
CRBP icon

Summit Securities Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Summit Securities Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41
Closed -$385 – 1194
2026
Q1 		$385 Buy
+41
New +$345 ﹤0.01% 1004

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Summit Securities Group's CRBP Position: Q2 2026 in Review

Summit Securities Group sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 41 shares — an estimated $385 sold.

Summit Securities Group first reported a position in CRBP in Q1 2026 and held it in 1 quarter. The position peaked at $385 in Q1 2026. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Summit Securities Group reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 41 Corbus Pharmaceuticals shares in Q2 2026, an estimated $385.
  • Summit Securities Group first reported a position in Corbus Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Summit Securities Group's Corbus Pharmaceuticals position peaked at $385 in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.